Press Release

CELLAAX Malaysia, a biopharmaceutical company engaged in the research and development of cellular therapy, recently completed its Phase 1 clinical trials to treat Retinitis Pigmentosa – a form of hereditary blindness that affects approximately two million people worldwide. The Phase 1 clinical trials which comprised 2 case studies, began in November 2020 and has since delivered promising results to move to phase 2 clinical trials.

CELLAAX Malaysia, a biopharmaceutical company engaged in the research and development of cellular therapy, recently announced its preliminary findings on the possible uses of stem cells derived from dental pulp to treat conditions of the nervous system.